[2]Chamoto K,Hatae R,Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy[J]. Int J Clin Oncol,2020,25:790-800. [3]Hayashi H,Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibito...
与regorafenib相比,同样的联合治疗在难治性转移性结直肠癌患者中也没有显示出任何益处(IMblaze370)。IDO抑制剂epacadostat 和pembrolizumab联用,最初的非随机试验数据在疗效方面很有希望,且联合治疗没有明显的增加毒性。但是3期pembrolizumab与epacadostat联合(KEYNOTE-252),没有任何益处和额外的毒性。免疫检查点抑制剂...
PD-1 inhibitors directly block the interaction between PD-1 on T cells and its ligands, PD-L1 and PD-L2, on tumor cells and other cells in the TME [41, 42]. This direct blockade may lead to a more robust and sustained activation of T cells, enhancing their ability to eliminate ...
The Second Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China, Email hhgwjb@163.com Purpose: To evaluate the clinical outcomes of lenvatinib plus PD-1 inhibitors (LP) and regorafenib (R) in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure....
经过分析可以发现,FP治疗方案中呋喹替尼是通过靶向抗肿瘤血管生成靶点VEGFR,联合PD-1抑制剂的免疫治疗作用,抑制肿瘤细胞的生长和增殖。 总之,对于难治性mCRC患者而言,呋喹替尼联合PD-1抑制剂这种免疫+靶向治疗模式,相较于传统的贝...
PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015). Article CAS PubMed PubMed Central Google Scholar Kim, Y. D. et al. HDAC inhibitor, CG-745, enhances the anti-cancer effect of anti-PD-1 immune checkpoint inhibitor by modulation of ...
PD-1抑制剂即将成为MSI-H/dMMR型mCRC患者一线标准治疗 后线治疗效果确立以后,多个不同 PD-1抑制剂在MSI-H/dMMR型mCRC患者一线治疗中的疗效进行探索,首先给出答案的是KEYNOTE-177。 KEYNOTE-177评估了帕博利珠单抗单药 vs. 标准疗法(化疗±贝伐珠单抗或西妥昔单抗)一线治疗MSI-H/dMMR型mCRC的疗效和安全性...
and it is insufficient to motivate effective antitumor immune response by blocking PD-1/PD-L1 axis. It has been validated that some combination therapies, including α-PD-1/PD-L1 plus chemotherapy, radiotherapy, angiogenesis inhibitors, targeted therapy, other immune checkpoint inhibitors, agonists of...
Pre-clinical models demonstrated that the combination of regorafenib and PD-1 blockade exhibited superior tumor growth suppression compared with either monotherapy [6,7]. A phase Ib study reported the ORR of combined treatment was 36 % and median PFS was almost 8 months [8], which demonstrated ...
PD-1/PD-L1 blockade, a novel strategy for targeting metastatic colorectal cancer: A systematic review and meta-analysis of randomized trials Currently, standard treatment of patients with metastatic colorectal cancer (mCRC) comprises chemotherapy (CT) and/or biological therapy (BT) and/or best s....